QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis

Sunitinib is widely used as a first-line treatment for advanced renal cell carcinoma (RCC). However, a number of patients with RCC who receive sunitinib develop drug resistance; and the biological mechanisms involved in resistance to sunitinib remain unclear. It has previously been suggested that th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Oncol
Main Authors: Zhao, Tangliang, Zhou, Yulin, Wang, Qingyun, Yi, Xiaoming, Ge, Silun, He, Haowei, Xue, Song, Du, Bowen, Ge, Jingping, Dong, Jie, Qu, Le, Wang, Linhui, Zhou, Wenquan
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2021
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8208629/
https://ncbi.nlm.nih.gov/pubmed/34036385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2021.5228
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados